Welcome to the e-CCO Library!

DOP26 Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C.G. af Björkesten1, T. Ilus2, T. Hallinen3, E. Soini3, A. Eberl1, K. Hakala4, M. Heikura5, E. Hirsi6, A. Jussila2, M. Kellokumpu7, R. Koskela8, I. Koskinen9, V. Moilanen10, C. Nielsen11, U. Nieminen1, H. Nuutinen12, M. Heikkinen13, U.M. Suhonen14, J. Tillonen15, K. Utriainen16, I. Vihriälä17, C. Wennerström18,19, A. Borsi20, R. Nissinen21, M. Koivunen21, T. Sipponen1

Created: Thursday, 30 January 2020, 10:12 AM
DOP26: Biological therapy increases NCR+ ILC3 levels in IBD patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Creyns*1,2, B. Verstockt2,3, J. Cremer1,2, V. Ballet3, M. Ferrante2,3, S. Vermeire2,3, J. Ceuppens1, G. Van Assche2,3, C. Breynaert1

Created: Friday, 22 February 2019, 9:41 AM
DOP26: Biological therapy increases NCR+ ILC3 levels in IBD patients
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Brecht Creyns
Created: Tuesday, 28 May 2019, 3:32 PM
Immunology, Innate lymphoid cell, Lymphocyte
Files: 1
DOP26: Burden of perianal disease and perianal surgery in Crohn's disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gonczi, L.(1);Lakatos, L.(2);Golovics, P.A.(3);Pandur, T.(4);David, G.(2);Erdelyi, Z.(2);Szita, I.(2);LakatosPhD, P.L.(5)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP26: COVID-19 vaccine effectiveness in Inflammatory Bowel Disease patients on tumor-necrosis factor inhibitors: Real world data from a mass-vaccination campaign
Year: 2022
Source: ECCO'22
Authors: Lev Zion, R.(1);Focht, G.(1);Lujan, R.(1);Mendelovici, A.(1);Friss, C.(1);Greenfeld, S.(2);Kariv, R.(3);Ben-Tov, A.(4,5);Matz, E.(6);Nevo, D.(7);Barak-Corren, Y.(8);Dotan, I.(9);Turner, D.(10);
Created: Friday, 11 February 2022, 3:52 PM
DOP26: Metagenomic and metabolomic profiles in IBD: understanding microbial and metabolic shifts from a large deeply phenotyped cohort
Year: 2024
Source: ECCO'24 Stockholm
Authors: Sokol, Harry
Created: Tuesday, 30 April 2024, 5:03 PM
DOP26: Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Clas-Göran Af Björkesten
Created: Tuesday, 23 June 2020, 5:40 PM
DOP26: Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Clas-Göran Af Björkesten
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP26: The relationship between vedolizumab therapeutic drug monitoring, biomarkers of inflammation, and clinical outcomes in Inflammatory Bowel Disease in the real-world setting
Year: 2021
Source: ECCO'21 Virtual
Authors: Afif, W.(1);Marshall, J.K.(2);Kaidanovich-Beilin, O.(3);Ward, R.(3);Seow, C.(4)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP27 Transanal minimally invasive surgery (TAMIS): A novel approach for treatment of pouch failure
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Van Praag BSc1, R. Hompes1, C. Buskens1, P. Tanis1, M. Duijvestein2, W. Bemelman1

Created: Thursday, 30 January 2020, 10:12 AM
DOP27: Disease activity patterns in the first 5 years after diagnosis in children with Crohn's disease: a population-based study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Distante, M.(1);Rotulo, S.(1)*;Ranalli, M.(1);Pedace, E.(1);Lionetti, P.(2);Arrigo, S.(3);Alvisi, P.(4);Miele, E.(5);Martinelli, M.(5);Zuin, G.(6);Bramuzzo, M.(7);Cananzi, M.(8);Aloi, M.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP27: Disease activity patterns in the first 5 years after diagnosis in children with Crohn’s disease: a population-based study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Silvia Rotulo
Created: Friday, 14 July 2023, 2:22 PM
DOP27: Humoral immune response after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases treated with immunosuppressive therapy - a Target to B! study
Year: 2022
Source: ECCO'22
Authors: Volkers , A.(1);Wieske , L.(2);van Dam , K.(2);Steenhuis , M.(3);Stalman , E.(2);Kummer , L.(2);van Kempen , Z.(4);Killestein , J.(4);Tas , S.(5);Boekel , L.(6);Wolbink , G.(6);Takkenberg , B.(1);Spuls , P.(7);Bosma , A.(7);Rutgers , B.(8);Verschuuren , J.(9);van Ouwerkerk , L.(10);van der Woude , D.(10);van Paassen , P.(11);Busch , M.(11);Brusse , E.(12);Hijnen , D.(13);ten Brinke , A.(3);Verstegen , N.(3);D'Haens , G.(1);van Ham , M.(3);Kuijpers , T.(14);Rispens , T.(3);Löwenberg , M.(1);Eftimov , F.(2); on behalf of the T2B! immunity against SARS-CoV-2 study group
Created: Friday, 11 February 2022, 3:52 PM
DOP27: Sequencing-based hematopoietic miRNA landscape reveals common and distinct features of autoimmune inflammatory phenotypes
Year: 2019
Source: ECCO '19 Copenhagen
Authors:

S. Juzenas*1,2, M. Hübenthal1, S. Zeißig3, N. Strüning4, A. Keller5, D. Schulte6, M. D’Amato7,8, M. Lindqvist9, J. Kupčinskas2,11, S. Schreiber1,12, J. Halfvarson13, G. Hemmrich-Stanisak1, A. Franke1

Created: Thursday, 28 February 2019, 8:13 AM
DOP27: The fibre fermentative capacity of the gut microbiota is diminished in children with Crohn’s Disease and it is independent of disease activity or treatment with exclusive enteral nutrition
Year: 2021
Source: ECCO'21 Virtual
Authors: Gkikas, K.(1);Logan, M.(1);Milling, S.(2);Ijaz, U.Z.(3);Hansen, R.(4);Russell, R.K.(5);Gerasimidis, K.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP27: Transanal minimally invasive surgery (TAMIS) – A noval approach for treatment of pouch failure
Year: 2020
Source: ECCO'20 Vienna
Authors: Elise Van Praag
Created: Tuesday, 23 June 2020, 5:40 PM
DOP27: Transanal minimally invasive surgery (TAMIS) – A noval approach for treatment of pouch failure
Year: 2020
Source: ECCO'20 Vienna
Authors: Elise Van Praag
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s disease: A pilot serum proteomic analysis of the PANTS cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Lin1,2, N. Chanchlani1,2, B.M. Invergo3, M.W. Anderson3, H.M. Guay4, M. Reppell4, J.W. Butler4, J.R. Goodhand1,2, T. Ahmad1,2, N.A. Kennedy1,2, Exeter IBD Pharmacogenetics Research Group

Created: Thursday, 30 January 2020, 10:12 AM